Bayer AG sells a minority stake in its contraceptives business to Apollo Global Management Inc. for €3 billion (about $3.4 billion). The companies say the transaction involves the contraceptives unit and is structured as a sale of a minority interest. Bayer plans to use proceeds to strengthen its financial position, including improving its capital structure. Other reporting links the funding to Bayer’s broader legal costs, including litigation connected to Roundup, noting that Bayer has been facing ongoing costs related to that matter.
Across the outlets, the core terms of the deal are consistent: the buyer is Apollo, the asset is Bayer’s contraceptives arm, and the consideration is €3 billion (approximately $3.4 billion). The reporting also aligns on Bayer’s intent to deploy the funds toward balance-sheet needs, though the emphasis differs, with one account focusing more directly on litigation-related pressures. The transaction represents a divestment intended to raise cash while keeping Bayer involved through its remaining stake.
